

David S H Bell Mb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3849234/publications.pdf>

Version: 2024-02-01

74
papers

4,082
citations

304743
22
h-index

114465
63
g-index

75
all docs

75
docs citations

75
times ranked

5551
citing authors

#	ARTICLE	IF	CITATIONS
1	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 2017, 23, 1-87.	2.1	766
2	Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. JAMA - Journal of the American Medical Association, 2004, 292, 2227.	7.4	710
3	Postprandial Hyperglycemia/Hyperlipidemia (Postprandial Dysmetabolism) Is a Cardiovascular Risk Factor. American Journal of Cardiology, 2007, 100, 899-904.	1.6	452
4	Heart Failure. Diabetes Care, 2003, 26, 2433-2441.	8.6	387
5	Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus. American Journal of Cardiology, 2012, 110, 826-833.	1.6	141
6	Metformin-Induced Vitamin B12 Deficiency Presenting as a Peripheral Neuropathy. Southern Medical Journal, 2010, 103, 265-267.	0.7	95
7	Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes, Obesity and Metabolism, 2019, 21, 210-217.	4.4	95
8	Effect of Rosiglitazone Versus Insulin on the Pancreatic β -Cell Function of Subjects With Type 2 Diabetes. Diabetes Care, 2004, 27, 2585-2589.	8.6	87
9	Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. Progress in Cardiovascular Diseases, 2017, 60, 422-434.	3.1	87
10	Differential Effects of β -Blockers on Albuminuria in Patients With Type 2 Diabetes. Hypertension, 2005, 46, 1309-1315.	2.7	76
11	Efficacy of Conversion From Bedtime NPH Insulin Injection to Once- or Twice-Daily Injections of Insulin Glargine in Type 1 Diabetic Patients Using Basal/Bolus Therapy. Diabetes Care, 2004, 27, 632-633.	8.6	75
12	Postprandial Dysmetabolism: the Missing Link Between Diabetes and Cardiovascular Events?. Endocrine Practice, 2008, 14, 112-124.	2.1	72
13	The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Current Medical Research and Opinion, 2006, 22, 287-296.	1.9	66
14	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. Diabetes, Obesity and Metabolism, 2019, 21, 1277-1290.	4.4	64
15	β -Cell rejuvenation with thiazolidinediones. American Journal of Medicine, 2003, 115, 20-23.	1.5	60
16	Do sulfonylurea drugs increase the risk of cardiac events?. Cmaj, 2006, 174, 185-186.	2.0	54
17	Long-Term Efficacy of Triple Oral Therapy for Type 2 Diabetes Mellitus. Endocrine Practice, 2002, 8, 271-275.	2.1	50
18	Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus. Mayo Clinic Proceedings, 2011, 86, 128-138.	3.0	50

#	ARTICLE	IF	CITATIONS
19	Strategies to prevent type 2 diabetes. Current Medical Research and Opinion, 2005, 21, 1107-1114.	1.9	40
20	Dosage Accuracy of Self-mixed vs Premixed Insulin. Archives of Internal Medicine, 1991, 151, 2265.	3.8	32
21	Resolution of Statin-Induced Myalgias by Correcting Vitamin D Deficiency. Southern Medical Journal, 2010, 103, 690-692.	0.7	31
22	The Role of C-Peptide Levels in Screening for Latent Autoimmune Diabetes in Adults. American Journal of Therapeutics, 2004, 11, 308-311.	0.9	23
23	Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1423-1428.	4.4	22
24	Hypertension and Diabetes—A Toxic Combination. Endocrine Practice, 2008, 14, 1031-1039.	2.1	21
25	Insulin Therapy in Diabetes Mellitus. Drugs, 2007, 67, 1813-1827.	10.9	20
26	Peripheral and autonomic syndromes. Postgraduate Medicine, 1982, 71, 50-67.	2.0	19
27	Diabetes: A Cardiac Condition Manifesting as Hyperglycemia. Endocrine Practice, 2008, 14, 924-932.	2.1	19
28	Use of Beta Blockers in the Patient With Diabetes. , 2003, 13, 116-123.		17
29	Treatment of diabetic hypertension. Diabetes, Obesity and Metabolism, 2009, 11, 433-444.	4.4	16
30	Diabetic ketoacidosis. Postgraduate Medicine, 1997, 101, 193-204.	2.0	15
31	Protean Manifestations of Vitamin D Deficiency, Part 1. Southern Medical Journal, 2011, 104, 331-334.	0.7	15
32	Stroke in the patient with diabetes (part 1) — Epidemiology, etiology, therapy and prognosis. Diabetes Research and Clinical Practice, 2020, 164, 108193.	2.8	14
33	Heart Failure in the Diabetic Patient. Cardiology Clinics, 2007, 25, 523-538.	2.2	13
34	Diabetogenic effects of cardioprotective drugs. Diabetes, Obesity and Metabolism, 2021, 23, 877-885.	4.4	13
35	Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: sequential or simultaneous start?. Diabetes, Obesity and Metabolism, 2017, 19, 909-911.	4.4	12
36	Dealing with diabetic nephropathy. Postgraduate Medicine, 1999, 105, 83-94.	2.0	10

#	ARTICLE	IF	CITATIONS
37	The Case for Combination Therapy as First-Line Treatment for the Type 2 Diabetic Patient. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 131-137.	1.8	10
38	Why I Initiate Therapy with Two Insulin Sensitizers in Patients with Type 2 Diabetes. Endocrine Practice, 2003, 9, 98-100.	2.1	9
39	Protean Manifestations of Vitamin D Deficiency, Part 3. Southern Medical Journal, 2011, 104, 340-344.	0.7	9
40	Are the Protean Effects of Pentoxifylline in the Therapy of Diabetes and Its Complications Still Relevant?. Diabetes Therapy, 2021, 12, 3025-3035.	2.5	9
41	Lower limb problems in diabetic patients. Postgraduate Medicine, 1991, 89, 237-244.	2.0	8
42	Triple oral therapy for type 2 diabetes. Diabetes Research and Clinical Practice, 2007, 78, 313-315.	2.8	8
43	Focusing on Cardiovascular Disease in Type 2 Diabetes Mellitus: An Introduction to Bromocriptine QR. Postgraduate Medicine, 2012, 124, 121-135.	2.0	8
44	Management of Type 2 Diabetes With Thiazolidinediones. , 2004, 14, 293-299.		7
45	Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient. Case Reports in Endocrinology, 2015, 2015, 1-4.	0.4	7
46	Riceabetes: is the association of type 2 diabetes with rice intake due to a high carbohydrate intake or due to exposure to excess inorganic arsenic?. Postgraduate Medicine, 2015, 127, 781-782.	2.0	6
47	Why Do Falls and Lower Limb Fractures Occur More Frequently in the Diabetic Patient and How Can They Be Prevented?. Diabetes Therapy, 2020, 11, 1687-1694.	2.5	6
48	Drugs for cardiovascular risk reduction in the diabetic patient. Current Diabetes Reports, 2001, 1, 133-139.	4.2	5
49	Insulin as Initial Therapy for Type 2 Diabetes is Not in the Patient's Best Interest. Endocrine Practice, 2004, 10, 208-212.	2.1	5
50	Peyronie Disease in Association with Carvedilol: A Case Report. Southern Medical Journal, 2008, 101, 1157-1158.	0.7	5
51	The Association of Obesity, Metabolic Syndrome, Diabetes, and Cardiovascular Disease with Nonalcoholic Fatty Liver Disease. Southern Medical Journal, 2009, 102, 991-992.	0.7	5
52	Aspirin in the prevention of cardiovascular events in patients with diabetes. Postgraduate Medicine, 2016, 128, 180-190.	2.0	5
53	Stroke in the patient with diabetes (Part 2) – Prevention and the effects of glucose lowering therapies. Diabetes Research and Clinical Practice, 2020, 164, 108199.	2.8	5
54	Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy. Diabetes Therapy, 2021, 12, 2795-2799.	2.5	5

#	ARTICLE	IF	CITATIONS
55	Treatment of type 2 diabetes. Postgraduate Medicine, 2006, 119, 8-14.	2.0	4
56	Metabolic syndrome and postoperative atrial fibrillation (POAF). European Heart Journal, 2009, 30, 1167-1168.	2.2	4
57	Lowering the Triglyceride/High-Density Lipoprotein Cholesterol and its Association With the Beneficial Impact of Pioglitazone on Coronary Atherosclerosis in the PERISCOPE Study Is Likely Due to Lowering Insulin Resistance. Journal of the American College of Cardiology, 2011, 58, 778.	2.8	4
58	Should we still be utilizing warfarin in the type 2 diabetic patient?. Diabetes, Obesity and Metabolism, 2018, 20, 2327-2329.	4.4	4
59	Current status of diabetes treatment. Southern Medical Journal, 2002, 95, 24-9.	0.7	3
60	Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus. Postgraduate Medicine, 2003, Spec No, 35-44.	2.0	3
61	Successful Utilization of Aliskiren, a Direct Renin Inhibitor in Bartter Syndrome. Southern Medical Journal, 2009, 102, 413-415.	0.7	2
62	Correlation between serum uric acid and diabetic peripheral neuropathy – association rather than causation. Journal of the Neurological Sciences, 2018, 390, 208.	0.6	2
63	Finally, after 56 years of type 1 diabetes: a regimen that works. Postgraduate Medicine, 2018, 130, 409-410.	2.0	2
64	Re: Diabetic Ketoacidosis in Patients with Type 2 Diabetes On Sglt-2 Inhibitors: an Ongoing Concern. Endocrine Practice, 2018, 24, 126.	2.1	2
65	Increase in glycated haemoglobin concentrations after unwarranted prescription changes. Diabetes, Obesity and Metabolism, 2018, 20, 2510-2511.	4.4	2
66	Alcohol Consumption as a Causator and/or an Accelerator of Neuropathy in People With Diabetes Is Regularly Overlooked. Diabetes Therapy, 2021, 12, 2631-2634.	2.5	2
67	Treatment of type 2 diabetes. Postgraduate Medicine, 2006, 119, 15-20.	2.0	1
68	Importance of Postprandial Glucose Levels in Type 2 Diabetes. Southern Medical Journal, 2009, 102, 553.	0.7	1
69	Chronic complications of diabetes. Southern Medical Journal, 2002, 95, 30-4.	0.7	1
70	Pantalone et al.: The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetologica, 2009, 46, 155-155.	2.5	0
71	Reply. American Journal of Cardiology, 2015, 115, 852-853.	1.6	0
72	Case Report: Efficient Avoidance of Hospitalization for Diabetic Ketosis Utilizing Technosphere Inhaled Insulin. Diabetes Therapy, 2020, 11, 1175-1177.	2.5	0

#	ARTICLE	IF	CITATIONS
73	Advances in diabetes for the millennium: the heart and diabetes. MedGenMed: Medscape General Medicine, 2004, 6, 7.	0.2	0
74	Testosterone Deficiency is Not Protective Against the Development of Adenocarcinoma of the Prostate in a Type 1 Diabetic Patient. Diabetes Therapy, 2022, , 1.	2.5	0